🇫🇷 PF-06882961 (Cohorts 1 and 2) in France

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2) regulatory status in France.

Marketing authorisation

ANSM

  • Status: approved

PF-06882961 (Cohorts 1 and 2) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in France

Frequently asked questions

Is PF-06882961 (Cohorts 1 and 2) approved in France?

Yes. ANSM has authorised it.

Who is the marketing authorisation holder for PF-06882961 (Cohorts 1 and 2) in France?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.